Orchard Therapeutics plc Quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD from Q4 2018 to Q3 2023

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
Orchard Therapeutics plc quarterly Accounts Receivable, after Allowance for Credit Loss, Current history and growth rate from Q4 2018 to Q3 2023.
  • Orchard Therapeutics plc Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending September 30, 2023 was $6.19M, a 46.2% increase year-over-year.
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2023 $6.19M +$1.95M +46.2% Sep 30, 2023 10-Q 2023-11-13
Q2 2023 $9.55M +$5.42M +131% Jun 30, 2023 10-Q 2023-08-10
Q4 2022 $8.47M +$6.99M +472% Dec 31, 2022 10-Q 2023-11-13
Q3 2022 $4.23M +$3.16M +295% Sep 30, 2022 10-Q 2022-11-14
Q2 2022 $4.13M Jun 30, 2022 10-Q 2022-08-04
Q1 2022 $4.11M Mar 31, 2022 10-Q 2022-05-12
Q4 2021 $1.48M +$602K +68.6% Dec 31, 2021 10-K 2023-03-14
Q3 2021 $1.07M -$2.11M -66.3% Sep 30, 2021 10-Q 2021-11-04
Q4 2020 $878K -$564K -39.1% Dec 31, 2020 10-K 2022-03-30
Q3 2020 $3.18M Sep 30, 2020 10-Q 2020-11-03
Q2 2020 $723K Jun 30, 2020 10-Q 2020-08-06
Q1 2020 $709K Mar 31, 2020 10-Q 2020-05-07
Q4 2019 $1.44M -$661K -31.4% Dec 31, 2019 10-K 2021-03-02
Q4 2018 $2.1M Dec 31, 2018 10-K 2020-02-27
* An asterisk sign (*) next to the value indicates that the value is likely invalid.